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BACKGROUND: Ultrasmall superparamagnetic particles of iron oxide 
(USPIO) detect cellular inflammation on magnetic resonance imaging (MRI). 
In patients with abdominal aortic aneurysm, we assessed whether USPIO-
enhanced MRI can predict aneurysm growth rates and clinical outcomes.
METHODS: In a prospective multicenter open-label cohort study, 342 
patients with abdominal aortic aneurysm (diameter ≥40 mm) were classified 
by the presence of USPIO enhancement and were monitored with serial 
ultrasound and clinical follow-up for ≥2 years. The primary end point was the 
composite of aneurysm rupture or repair.
RESULTS: Participants (85% male, 73.1±7.2 years) had a baseline aneurysm 
diameter of 49.6±7.7 mm, and USPIO enhancement was identified in 146 
(42.7%) participants, absent in 191 (55.8%), and indeterminant in 5 (1.5%). 
During follow-up (1005±280 days), 17 (5.0%) abdominal aortic aneurysm 
ruptures, 126 (36.8%) abdominal aortic aneurysm repairs, and 48 (14.0%) 
deaths occurred. Compared with those without uptake, patients with USPIO 
enhancement have increased rates of aneurysm expansion (3.1±2.5 versus 
2.5±2.4 mm/year, P=0.0424), although this was not independent of current 
smoking habit (P=0.1993). Patients with USPIO enhancement had higher rates 
of aneurysm rupture or repair (47.3% versus 35.6%; 95% confidence intervals, 
1.1–22.2; P=0.0308). This finding was similar for each component of rupture 
(6.8% versus 3.7%, P=0.1857) or repair (41.8% versus 32.5%, P=0.0782). 
USPIO enhancement was associated with reduced event-free survival for 
aneurysm rupture or repair (P=0.0275), all-cause mortality (P=0.0635), and 
aneurysm-related mortality (P=0.0590). Baseline abdominal aortic aneurysm 
diameter (P<0.0001) and current smoking habit (P=0.0446) also predicted the 
primary outcome, and the addition of USPIO enhancement to the multivariate 
model did not improve event prediction (c-statistic, 0.7935–0.7936).
CONCLUSIONS: USPIO-enhanced MRI is a novel approach to the 
identification of aortic wall cellular inflammation in patients with abdominal 
aortic aneurysms and predicts the rate of aneurysm growth and clinical 
outcome. However, it does not provide independent prediction of aneurysm 
expansion or clinical outcomes in a model incorporating known clinical risk 
factors.
CLINICAL TRIAL REGISTRATION: URL: http://www.isrctn.com. Unique 
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Aortic Wall Inflammation Predicts 
Abdominal Aortic Aneurysm Expansion, 
Rupture, and Need for Surgical Repair
Correspondence to: Rachael 
Forsythe, British Heart Foundation 
Centre for Cardiovascular 
Science, University of Edinburgh, 
Chancellor’s Building, 49 Little 
France Crescent, Edinburgh, 
Scotland, EH16 4SA. E-mail 
Rachael.Forsythe@ed.ac.uk
Sources of Funding, see page 795
Key Words: abdominal aortic 
aneurysm ◼ MRI ◼ repair 
◼ rupture 
The MA3RS Study 
 Investigators
© 2017 The Authors. Circulation 
is published on behalf of the 
American Heart Association, Inc., 
by Wolters Kluwer Health, Inc. This 
is an open access article under the 
terms of the Creative Commons 
Attribution License, which permits 
use, distribution, and reproduction 
in any medium, provided that the 
original work is properly cited.
D
ow
nloaded from
 http://ahajournals.org by on January 29, 2020
The MA3RS Study Investigators
August 29, 2017 Circulation. 2017;136:787–797. DOI: 10.1161/CIRCULATIONAHA.117.028433788
Abdominal aortic aneurysms have a prevalence of 5% in 65- to 74-year-old men and, when rup-tured, are associated with a mortality of ≤90%.1 
At a population level, ruptured aortic aneurysms are a 
major cause of death, being the 13th most common 
cause of death and accounting for >150 000 deaths in 
2013.2 Preemptive elective open surgical or endovascu-
lar repair can be life-saving and is considered when the 
abdominal aortic aneurysm diameter is >55 mm, is rap-
idly expanding (≥10 mm/year), or causes symptoms.3–5
Abdominal aortic aneurysms are usually associated 
with no symptoms and are often identified incidentally 
or as part of an ultrasound-based screening program. 
Population screening has been established in some 
countries and is associated with a halving of the mortal-
ity associated with abdominal aortic aneurysms.6,7 How-
ever, continued surveillance of aneurysms is challenging 
because of the nonlinearity and unpredictability of ex-
pansion rates,8 although the best current predictor of an-
eurysm expansion and rupture is the baseline aneurysm 
diameter.1,9 Furthermore, the pathophysiological mecha-
nisms underlying aneurysm expansion remain uncertain, 
and the role of cellular inflammation and macrophage 
infiltration has been debated. Last, ≤20% of ruptured 
abdominal aortic aneurysms are <55 mm in diameter, 
and 40% of patients with aneurysm diameters between 
70 and 100 mm do not experience aneurysm rupture.10 
Therefore, an unmet clinical need exists to identify more 
reliable methods of identifying those patients at risk of 
abdominal aortic aneurysm expansion and rupture,11,12 
and techniques that assess both the structure and biol-
ogy of aneurysms hold considerable promise.
Ultrasmall superparamagnetic particles of iron oxide 
(USPIO) constitute a class of magnetic resonance im-
aging (MRI) contrast agent taken up by tissue-resident 
macrophages and can be used to identify cellular inflam-
mation within tissues,13,14 including abdominal aortic 
aneurysms.15,16 In a small pilot study of 29 patients with 
abdominal aortic aneurysm,15 we have previously dem-
onstrated that USPIO enhancement on MRI is associated 
with macrophage infiltration of the abdominal aortic an-
eurysm wall and more rapid rates of abdominal aortic an-
eurysm expansion. We therefore aimed to validate these 
preliminary findings in a larger multicenter cohort of pa-
tients and determine whether USPIO-enhanced MRI could 
predict the rate of abdominal aortic aneurysm expansion 
and subsequent rates of rupture or surgical repair.
METHODS
Study Design
The MA3RS study (MRI Using Ultrasound Superparamagnetic 
Particles of Iron Oxide to Predict Clinical Outcome in Patients 
Under Surveillance for Abdominal Aortic Aneurysms) was a 
prospective multicenter observational open-label cohort study 
of patients under routine ultrasound surveillance for abdomi-
nal aortic aneurysm. The research design and protocol has 
been described previously (ISRCTN.com. Unique identifier: 
ISRCTN76413758).17 The study was approved by the local 
research ethics committee (12/ES/0068), and the use of feru-
moxytol was given clinical trial authorization by the Medicines 
and Healthcare products Regulatory Authority of the United 
Kingdom (EudraCT Number 2012-002488-25).
Study Population
Consecutive patients were recruited from 3 centers in Scotland 
(Royal Infirmary of Edinburgh, Western Infirmary of Glasgow, 
and Forth Valley Royal Hospital in Larbert) between November 
8, 2012, and December 5, 2014. Inclusion criteria were 
age >40 years, maximum anteroposterior abdominal aortic 
aneurysm diameter ≥40 mm by abdominal ultrasound, and 
under ultrasound surveillance as part of routine clinical care. 
Exclusion criteria included patients with planned repair of 
abdominal aortic aneurysm, known inflammatory aneurysm, 
aneurysm arising from a connective tissue disorder, women 
of childbearing potential, renal failure (estimated glomerular 
filtration rate ≤30 mL/min/1.73 m2), and contraindication to 
MRI or ferumoxytol. All participants gave written informed 
consent to participate in the study.
Study Protocol
Participants received a baseline assessment within 6 
weeks of the screening abdominal ultrasound. Participant 
Clinical Perspective
What Is New?
• In this proof-of-concept phase 2 study, we dem-
onstrate for the first time that functional imaging 
of abdominal aortic aneurysms can predict disease 
progression and clinical events.
• Aortic wall inflammation detected by ultrasmall 
superparamagnetic particles of iron oxide–
enhanced magnetic resonance imaging predicts 
the rate of aneurysm growth and the risk of aneu-
rysm rupture or repair as well as being associated 
with all-cause and aneurysm-related mortality.
What Are the Clinical Implications?
• Multivariate analysis demonstrated that ultrasmall 
superparamagnetic particles of iron oxide–
enhanced magnetic resonance imaging does not 
appear to improve risk stratification beyond current 
predictors of clinical outcome, including ultrasound 
measures of aneurysm diameter.
• This technique may be a useful adjunctive imag-
ing approach in those with high-risk or borderline 
aneurysm sizes or those with larger aneurysms, 
where the balance of risk and benefit is uncertain.
• This approach may also have utility in assessing 
candidate anti-inflammatory therapies targeted at 
reducing disease progression.D
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characterization comprised a full clinical assessment, USPIO-
enhanced MRI, and computed tomography aortography. The 
scanning protocols and image analysis techniques have been 
described previously.15,17 In brief, patients underwent a base-
line 3T MRI (Magnetom Verio 3T, Siemens Healthcare) before 
receiving an intravenous infusion of a weight-adjusted dose 
of USPIO (4 mg/kg of ferumoxytol; Rienso). A second MRI 
scan was performed 24 to 36 hours after USPIO administra-
tion. Two trained observers performed image analysis using 
bespoke software that compared before and after contrast 
images using semiautomatic registration. To calculate the 
degree of USPIO enhancement, color maps were generated 
to depict the percentage change in T2*, which is the decay 
constant for the exponential decay of signal over time. Using 
the predefined threshold of ≥71% change in T2*, each color 
map was independently classified by 2 trained observers into 
patients with or without USPIO enhancement (≥10 contigu-
ous voxels15) within the wall of the abdominal aortic aneu-
rysm (Figure  1). Discordant classifications were resolved by 
consensus.
Clinical Follow-Up
Patients were reviewed every 6 months in the research clinic 
for ≥24 months. Structured follow-up data were collected on 
abdominal aortic aneurysm events, hospital admissions, and 
other relevant clinical data. Clinical events were verified inde-
pendently using electronic health records and public registry 
data as described previously.18,19 Serial maximum anteropos-
terior diameters were obtained by ultrasound in dedicated 
abdominal aortic aneurysm surveillance clinics performed by 
trained specialist vascular practitioners who were blinded to 
USPIO-enhanced MRI findings. We have previously reported 
interobserver coefficient of variation of aortic diameter mea-
surements of 3.5%.20 Participants who were unable to attend 
for subsequent research visits were followed up through elec-
tronic health records as described previously.18,19
Clinical End Points and Adjudication
Clinical data from clinic visits, research database, electronic 
health records, primary care contacts, and the General 
Register Office were reviewed, and clinical end points were 
adjudicated by an independent Clinical End Point Committee. 
The committee members were blinded to the MRI findings. 
Follow-up was censored on November 21, 2016, or at the 
time of event.
Statistical Analysis
The primary end point was the composite of abdominal aortic 
aneurysm rupture or repair. We estimated that 130 events 
would be required to have adequate sensitivity to deter-
mine the added value of USPIO-enhanced MRI to predict the 
occurrence of the primary end point. Previous data from the 
United Kingdom have suggested a 2-year event rate of 41% 
in patients under surveillance for abdominal aortic aneu-
rysm.21 Therefore, we aimed to recruit ≈350 patients, with 
an expected dropout rate of 10%, resulting in ≥317 patients 
with 130 events to be included in the final analysis.
Categorical data are presented using counts and 
percentages, continuous variables are presented using 
Figure 1. MRI of abdominal aortic aneurysm.  
A, T2-weighted HASTE (Half Fourier Acquisition Single Shot 
Turbo Spin Echo) sequence in the sagittal plane. B, Cross-
sectional image (dashed line in A) using a T2-weighted 
fat-saturated sequence to highlight intraluminal thrombus 
(white) within the aneurysm. C, T2* map (blue) overlying the 
T2-weighted HASTE sequence (B), demonstrating enhance-
ment of the posterior aneurysm wall with ultrasmall super-
paramagnetic particles of iron oxide (USPIO) (red).
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mean±standard deviation, and absolute differences are pre-
sented with 95% confidence intervals (CIs). Comparisons 
in baseline characteristics were made using either a bino-
mial test for proportions in the case of categorical data or 
by 2-sample t test for continuous data. Aneurysm growth 
rate was determined from serial ultrasound measurements 
using a linear regression model that was fitted to all avail-
able data, and the slope was used to determine the aneu-
rysm growth rate per year. The primary and clinical event 
end points were assessed by log-rank test and are presented 
as Kaplan-Meier curves. Cox proportional hazards models 
were generated to include the baseline covariates of sex, 
smoking, systolic blood pressure, and baseline aneurysm 
diameter determined by ultrasound. The additional value of 
USPIO enhancement was assessed by the c-statistic and net 
reclassification index.22–24 Statistical significance was taken 
as 2-sided P<0.05.
RESULTS
We screened ≈2000 patients attending the outpa-
tient vascular clinics of the study centers and identified 
741 potentially eligible patients, of whom ultimately 
361 (48.7%) were recruited into the study (Figure 2). 
Nineteen patients were subsequently withdrawn pre-
dominantly because they were unable to undergo re-
peated MRI because of claustrophobia. The final study 
population comprised 342 participants who were pre-
dominantly elderly male current or former smokers 
with hypercholesterolemia and hypertension (Table 1). 
No serious adverse events or reactions to intravenous 
ferumoxytol administration occurred; the medication 
was generally well tolerated by all participants. Mild as-
ymptomatic hypotension possibly related to ferumoxy-
tol was noted in 1 subject but required no action or 
intervention.
USPIO enhancement of the abdominal aortic aneu-
rysm wall was identified in 146 (42.7%) participants, 
was absent in 191 (55.8%), and was indeterminate in 
5 (1.5%). USPIO enhancement was strongly associated 
with current smoking status as well as baseline abdom-
inal aortic aneurysm diameter and the presence of a 
common iliac aneurysm (Table 1).
Aneurysm Growth Rate
On ultrasound, baseline maximum abdominal aortic 
aneurysm diameter was 49.6±7.7 mm and was slightly 
larger in patients with USPIO enhancement (Table 1). 
The abdominal aortic aneurysm growth rate during the 
trial was 2.8±2.4 mm/year (n=279) and was greater 
in patients with USPIO enhancement (3.1±2.5 ver-
sus 2.5±2.4 mm/year; difference 0.6 mm/year; 95% 
CI, 0.02‒1.2; P=0.0424). Current smoking status 
(P=0.0305), but not aneurysm diameter (P=0.1853), 
baseline systolic blood pressure (P=0.6994), or USPIO 
enhancement (P=0.1993), was an independent predic-
tor of aneurysm growth rate.
Clinical Follow-Up
All participants were followed up for a mean of 
1005±280 days. Overall, the primary end point oc-
curred in 140 (40.9%) subjects with 17 abdominal aor-
tic aneurysm ruptures and 126 abdominal aortic aneu-
rysm repairs (Table 2): 3 subjects underwent repair after 
rupture. In all, 48 (14.0%) deaths occurred, of which 
one third were related to abdominal aortic aneurysm 
(17 [35.4%]), and a quarter were related to other car-
diovascular causes (12 [25.0%]).
Rupture or Repair
The primary end point occurred more frequently in par-
ticipants with USPIO enhancement of abdominal aor-
tic aneurysm (69/146=47.3% versus 68/191=35.6%; 
difference 11.7%, 95% CI 1.1–22.2%; P=0.0308) 
and was associated with a reduced event-free survival 
(P=0.0275; Figure  3). This finding was consistent for 
both components of the end point (Table  2). In con-
trast with female sex (hazard ratio [HR], 0.952; 95% CI, 
0.589‒1.540; P=0.8413) and systolic blood pressure 
(HR, 0.997; 95% CI, 0.988‒1.005; P=0.4492), baseline 
abdominal aortic aneurysm diameter (HR, 1.077; 95% 
CI, 1.061‒1.094; P<0.0001), and current smoking hab-
it (HR, 1.464; 95% CI, 1.001–2.120; P=0.0433) were 
Figure 2. Consolidated Standards of Reporting Trials 
(CONSORT) diagram of participant recruitment.
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the main predictors of the primary end point. The ad-
dition of USPIO enhancement to the model (HR, 1.003; 
95% CI, 0.700–1.439; P=0.9849) did not improve the 
prediction of events (c-statistic, 0.7924‒0.7926) or the 
unconditional net reclassification (‒13.5%; 95% CI, 
‒36.4 to 9.3). This finding was true for both compo-
nents of the end point: (1) aneurysm rupture, c-statis-
tic, 0.6317 to 0.6304, and net reclassification, 29.9% 
(95% CI, ‒22.0 to 81.9); and (2) aneurysm repair, c-
statistic, 0.8000 to 0.7996, and net reclassification, 
‒9.9% (95% CI, ‒33.4 to 13.7). 
All-cause and abdominal aortic aneurysm-related death 
appeared to be more frequent in participants with USPIO 
enhancement of the abdominal aortic aneurysm (Table 2 
and Figure 3) but fell short of statistical significance.
In post hoc analysis, we explored whether USPIO 
enhancement varied according to aneurysm size. We 
dichotomized the population at the mean diameter 
into smaller (diameter 40–49 mm; n=187) and larg-
er (diameter ≥50 mm; n=155) aneurysms. The rate 
of USPIO enhancement was lower in patients with 
smaller aneurysms: 65 (35.1%) versus 81 (53.3%) in 
those with larger aneurysms, difference 18.2% (95% 
CI, 7.7–28.9; P=0.0008). However, in patients with 
smaller aneurysms, USPIO enhancement was associ-
ated with a doubling in the rate of repair or rupture 
without an effect on mortality (Table 3), whereas in 
those with larger aneurysms, the reverse occurred, 
with a more than doubling of mortality but no effect 
on the primary end point (Table 4).
Table 1. Baseline Characteristics of Participants
Characteristic
All 
Participants
(n=342)
Indeterminant 
USPIO 
Enhancement
 (n=5)
No USPIO 
Enhancement
(n=191)
USPIO 
Enhancement
(n=146)
Difference
(95% CI) P Value
  Age, y 73.1±7.2 75·0±7.0 73·4±7.5 72·8±6.8 ‒0.6 (‒2.2 to 0.9) 0.4330
  Male 292 (85.4) 5 (100) 166 (86·9) 121 (82·9) ‒4.0 (‒11.8 to 3.7) 0.3019
  Systolic blood pressure, mm Hg 139.6±21.2 151·6±5·3 140·3±21·3 138·2±21·3 ‒2.1 (‒6.8 to 2.5) 0.3610
  Diastolic blood pressure, mm Hg 81.4±10.8 87·0±10·7 80·5±10·3 82·3±11·3 1.9 (‒0.4 to 4.2) 0.1101
  Heart rate/min 70.7±10.1 71·6±12·1 70·0±10·1 71·5±10·0 1.5 (‒0.7 to 3.7) 0.1779
  Body mass index, kg/m2 27.6±4.2 25·0±3·1 28·0±4·2 27·2±4·2 ‒0.8 (‒1.7 to 0.1) 0.0729
  Creatinine, µmol/L 89.9±23.4 76·2±9·7 90·0±21·1 90·3±26·5 0.4 (‒4.9 to 5.7) 0.8912
  Cholesterol, mmol/L 4.5±1.0 5·0±1·9 4·5±1·0 4·5±1·0 0.0 (‒0.2 to 0.3) 0.7732
  Current smoker 101 (29·5) 4 (80) 40 (20·9) 57 (39·0) 18.1 (8.3‒27.9)* 0.0003*
  Former smoker 195 (57.0) 1 (20) 120 (62.8) 74 (50.7)   
  Never smoker 46 (13.5) 0 (0) 31 (16.2) 15 (10.3)   
Aneurysm
  Abdominal aortic aneurysm diameter, mm 49.6±7.7 54·4±12·3 48·2±6·6 51·4±8·4 3.2 (1.5‒4.8) 0·0002
  Concurrent iliac artery aneurysm 66 (19.3) 1 (20) 29 (15·2) 36 (24·7) 9.5 (0.8‒18.1) 0·0289
Past medical history
  Hypertension 246 (71.9) 3 (60) 143 (74·9) 100 (68·5) ‒6.4 (‒16·1 to 3·4) 0·1959
  Hypercholesterolemia 257 (75.1) 2 (40) 146 (76·4) 109 (74·7) –1·8 (‒11·1 to 7·5) 0·7056
  Diabetes mellitus 47 (13.7) 0 (0) 31 (16·2) 16 (11·0) –5·3 (‒12·6 to 2·0) 0·1663
  Family history of abdominal aortic aneurysm 61 (17.8) 0 (0) 32 (16·8) 29 (19·9) 3·1 (‒5·3 to 11·5) 0·4626
  Ischemic heart disease 125 (36·5) 1 (20) 69 (36·1) 55 (37·7) 1·6 (‒8·9 to 12·0) 0·7706
  Peripheral vascular disease 66 (19·3) 1 (20) 34 (17·8) 31 (21·2) 3·4 (‒5·1 to 12·0) 0·4288
  Cerebrovascular disease 46 (13·5) 0 (0) 22 (11·5) 24 (16·4) 4·9 (‒2·6 to 12·5) 0·1924
Baseline medication
  Antiplatelet therapy 224 (65·5) 2 (40) 127 (66·5) 95 (65·1) –1·4 (‒11·7 to 8·8) 0·7847
  Statin therapy 270 (78·9) 4 (80) 151 (79·1) 115 (78·8) –0·3 (‒9·1 to 8·5) 0·9483
  Anticoagulant therapy 25 (7·3) 0 (0) 16 (8·4) 9 (6·2) –2·2 (‒7·8 to 3·3) 0·4425
  Beta blocker therapy 120 (35·1) 1 (20) 72 (37·7) 47 (32·2) –5·5 (‒15·7 to 4·7) 0·2948
  Angiotensin-converting enzyme inhibitor therapy 123 (36·0) 2 (40) 68 (35·6) 53 (36·3) 0·7 (‒9·6 to 11·0) 0·8945
Values are mean±SD or n (%). CI indicates confidence interval; and USPIO, ultrasmall superparamagnetic particles of iron oxide. 
*Current smoker versus combined former smoker and never smoker.
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DISCUSSION
In a prospective multicenter observational cohort study, 
we have demonstrated that USPIO-enhanced MRI pre-
dicts the rate of aneurysm expansion as well as the fu-
ture risk of abdominal aortic aneurysm rupture or re-
pair. This prospective clinical study of MRI in patients 
with abdominal aortic aneurysms is the largest and the 
first to report on an imaging technique that identifies 
cellular inflammation and predicts disease progression 
and outcome. This study suggests a central role of cel-
lular inflammation in the pathophysiology, progression, 
and outcome of abdominal aortic aneurysm disease.
Abdominal aortic aneurysm expansion is driven by 
several potential pathogenetic mechanisms that are as-
sociated with inflammation and tissue degradation.1,11 
Macrophages are central to many of these processes,25 
and their depletion appears to prevent aneurysm for-
mation or progression in preclinical models of abdomi-
nal aortic aneurysm.26 Noninvasive in vivo imaging of 
tissue-resident macrophages would therefore seem an 
intuitive and promising approach in patients with ab-
dominal aortic aneurysm, but until now this approach 
has not been prospectively tested in large clinical co-
horts.11,12,27 We here report the first study in a large clin-
ical cohort to image tissue-resident macrophages with 
USPIO-enhanced MRI, and we demonstrate that USPIO 
enhancement is associated with more rapid abdomi-
nal aortic aneurysm growth rates and adverse clinical 
outcomes. This finding provides strong support for the 
concept that imaging the biology of abdominal aortic 
aneurysm may be a promising new approach to risk 
stratify and manage patients with this disease.11
The rate of abdominal aortic aneurysm growth has 
previously been shown to be predicted by smoking sta-
tus, aneurysm size, and the presence of common iliac 
aneurysms.9,28 Indeed, a smoking habit is the principal 
modifiable risk factor for abdominal aortic aneurysm 
progression and rupture and is the main focus of life-
style modification in these patients. We here demon-
strate that USPIO-enhanced MRI is associated with these 
3 risk factors. In particular, current smoking was an in-
dependent risk factor for abdominal aortic aneurysm 
growth, and intriguingly, USPIO enhancement was twice 
as frequent in current smokers. We know that smoking 
promotes inflammation, macrophage-mediated injury, 
and vascular dysfunction.29–31 This finding suggests a 
potential mechanistic link between smoking and mac-
rophage-driven abdominal aortic aneurysm inflamma-
tion. Indeed, components of cigarette smoke, such as 
3,4-benzopyrene, promote macrophage infiltration of 
abdominal aortic aneurysm, leading to increased matrix 
metalloproteinase expression and vascular smooth mus-
Table 2. Clinical Outcome Events in All Patients
Clinical Event
All Participants
(n=342)
Indeterminant 
USPIO 
Enhancement
 (n=5)
No USPIO 
Enhancement
(n=191)
USPIO 
Enhancement
(n=146)
Difference
(95% CI) P Value
Abdominal aortic aneurysm event
  Rupture/repair 140 (40·9) 3 (60) 68 (35·6) 69 (47·3) 11·7 (1.1‒22.2) 0·0308
  Rupture 17 (5·0) 0 (0) 7 (3·7) 10 (6·8) 3·2 (‒1·7 to 8·1) 0·1857
  Repair 126 (36·8) 3 (60) 62 (32·5) 61 (41·8) 9·3 (‒1·1 to 19·7) 0·0782
   Endovascular aneurysm repair 53 (15·5) 1 (20) 29 (15·2) 23 (15·8)   
   Open repair 73 (21·3) 2 (40) 33 (17·3) 38 (26·0)   
   Elective surgery 120 (35·1) 3 (60) 58 (30·4) 59 (40·4)   
   Emergency surgery 6 (1·8) 0 (0) 4 (2·1) 2 (1·4)   
Death
  All cause 48 (14·0) 1 (20) 21 (11·0) 26 (17·8) 6·8 (‒0·8 to 14·4) 0·0736
  Cardiovascular, related to 
abdominal aortic aneurysm
17 (5·0) 0 (0) 6 (3·1) 11 (7·5) 4·4 (‒0·6 to 9·3) 0·0679
  Cardiovascular, not related to 
abdominal aortic aneurysm 
12 (3·5) 0 (0) 8 (4·2) 4 (2·7)   
   Stroke 2 (0·6) 0 (0) 2 (1·0) 0 (0)   
   Myocardial infarction 8 (2·3) 0 (0) 4 (2·1) 4 (2·7)   
   Other cardiovascular 2 (0·6) 0 (0) 2 (1·0) 0 (0)   
  Noncardiovascular 19 (5·6) 1 (20) 7 (3·7) 11 (7·5)   
   Malignancy 12 (3·5) 1 (20) 4 (2·1) 7 (4·8)   
   Other 7 (2·0) 0 (0) 3 (1·6) 4 (2·7)   
Values are n (%). CI indicates confidence interval; and USPIO, ultrasmall superparamagnetic particles of iron oxide. D
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cle apoptosis.32 Using adoptive transfer experiments, 
Jin and colleagues33 have further shown that in vivo ex-
posure of leukocytes to smoke can accelerate the pro-
gression of aneurysm disease in smoke-free animals. In 
this context, our USPIO data suggest that macrophage-
mediated inflammation may be the mechanistic link to 
explain the association between smoking and disease 
progression in patients with abdominal aortic aneurysm.
The primary end point of the study was the rate of 
abdominal aortic aneurysm rupture or repair. Although 
the rate was higher in patients with USPIO enhancement 
on MRI, it was not independent of known predictors of 
outcome, including baseline abdominal aortic aneurysm 
diameter and smoking habit. Indeed, incorporation of 
USPIO-enhanced MRI did not improve the discrimination 
of a model incorporating these known clinical risk fac-
tors. This finding likely reflects the mutual interdepen-
dence and potential causal association of these factors, 
namely, that USPIO enhancement highlights areas of 
smoking-induced cellular inflammation within the aneu-
rysm, which causes more rapid expansion and increase 
in the aneurysm diameter, leading to aneurysm rupture 
or triggering of the threshold for repair.
Ultrasound measurements of abdominal aortic aneu-
rysm diameter are the mainstay of clinical management 
and the principal determinant of the timing of elective 
surgical repair. Therefore, their dominant effect on the 
primary end point is perhaps not surprising, especially 
as most events were because of elective surgical repair. 
Given that the clinicians were blind to the results of the 
USPIO-enhanced MRI, it would be challenging to dem-
onstrate that it could lead to any changes in the rate 
of elective surgical repair. We therefore explored other 
measures of outcome that were independent of elective 
surgical repair. We found that USPIO enhancement ap-
peared to be greater in those with emergent abdominal 
aortic aneurysm-related events, including abdominal 
aortic aneurysm rupture and abdominal aortic aneu-
rysm-related mortality, although the absolute number 
of events was small and fell just short of achieving sta-
tistical significance. Given the small number of emer-
gent events, our study did not have sufficient power to 
determine whether USPIO enhancement could provide 
clinically useful information that could independently 
predict emergent events. However, post hoc analyses 
did suggest that USPIO-enhanced MRI predicted overall 
mortality in patients with larger aneurysms.
Although USPIO-enhanced MRI was not an inde-
pendent predictor of outcome across the whole study 
population, it identified aneurysm disease activity, cor-
related with rates of aneurysm expansion, and appeared 
to predict clinical outcome, including rupture and death. 
Figure 3. Major clinical events in the MA3RS study.  
Abdominal aortic aneurysm rupture or repair (primary end point) (A), all-cause mortality (B), and aneurysm-related mortality 
(C) in participants with (red) and without (blue) ultrasmall superparamagnetic particles of iron oxide (USPIO) enhancement of 
the aneurysm wall. Cross-hairs represent individual censoring.
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If future studies confirm the utility of USPIO-enhanced 
MRI, how would it be applied in the clinic? For some pa-
tients, treatment decisions are not straightforward. For 
example, abdominal pain in a patient with an aortic an-
eurysm may be because of other abdominal pathology 
and not the aneurysm. Urgent repair may be unhelpful 
in such circumstances and associated with considerable 
risk. Furthermore, decisions to undertake surgical repair 
can be challenging in those with high-risk or morpho-
logically atypical aneurysms <55 mm, those with bor-
derline aneurysm sizes of 50 to 55 mm (especially in 
women), or those with larger aneurysms where the bal-
ance of risk and benefit is uncertain. Additional informa-
tion regarding disease activity that is tied to disease pro-
gression and adverse clinical outcome may be helpful in 
guiding such decisions. The value of USPIO-enhanced 
MRI may also differ according to aneurysm size, with the 
prediction of future aneurysm repair greater in patients 
with smaller aneurysms and the future mortality risk 
more marked in those with larger aneurysms. Although 
not directly tested here, USPIO-enhanced MRI may as-
sist the clinician in making these difficult management 
decisions that are associated with significant potential 
benefits and hazards. This requires further investigation.
No definitive medical treatments can impact disease 
progression in this serious and potentially fatal condi-
tion. Novel anti-inflammatory or other disease-mod-
ifying therapies are potential interventions that could 
address this unmet clinical need. USPIO-enhanced MRI 
would provide a useful surrogate biomarker of efficacy 
in such early proof-of-concept clinical trials. Reduction 
in USPIO enhancement would be predicted to corre-
late with reduced cellular inflammation within the an-
eurysm and consequently reduced rates of expansion. 
This theory merits further investigation.
Our study has a number of strengths. It was a multi-
center prospective observational cohort study, which en-
sured blinding of the USPIO-enhanced MRI findings from 
the patients, vascular technicians, and attending clini-
cians, and was therefore independent of clinical decision 
making. It was an adequately sized phase 2 proof-of-con-
cept trial that was ≈10-fold larger than previous studies in 
this area.15,34 The study also achieved its predicted event 
rates and met its primary end point, although not inde-
pendent of known clinical predictors. However, the inclu-
sion of elective surgical repair in the primary end point 
generates some challenges in interpretation because of 
the ultrasound- and diameter-guided decision making 
for elective surgical repair. The prediction of emergent 
events appears promising but will require a much larg-
er study with greater power to confirm these findings. 
Finally, USPIO-enhanced MRI is resource intensive and 
Table 3. Clinical Outcome Events in Patients With Small Aneurysms (Diameter, 40–49 mm)
Clinical Event
All 
Participants
(n=187)
Indeterminant 
USPIO 
Enhancement
 (n=2)
No USPIO 
Enhancement
(n=120)
USPIO 
Enhancement
(n=65)
Difference
(95% CI) P Value
Abdominal aortic aneurysm event
  Rupture/repair 42 (22.5) 0 (0) 20 (16.7) 22 (33.8) 17·2 (3.9‒30.5) 0·0077
  Rupture 4 (2·1) 0 (0) 2 (1·7) 2 (3·1) 1·4 (‒3·4 to 6·2) 0·6136*
  Repair 38 (20·3) 0 (0) 18 (15·0) 20 (30·8) 15·8 (2·9‒28·7) 0·0113
   Endovascular aneurysm repair 19 (10·2) 0 (0) 9 (7·5) 10 (15·4)   
   Open repair 19 (10·2) 0 (0) 9 (7·5) 10 (15·4)   
   Elective surgery 36 (19·3) 0 (0) 16 (13·3) 20 (30·8)   
   Emergency surgery 2 (1·1) 0 (0) 2 (1·7) 0 (0)   
Death
  All cause 20 (10·7) 1 (50) 14 (11·7) 5 (7·7) ‒4·0 (‒12·6 to 4·7) 0·3953
  Cardiovascular, related to abdominal aortic 
aneurysm
4 (2·1) 0 (0) 2 (1·7) 2 (3·1) 1·4 (‒3·4 to 6·2) 0·6136*
  Cardiovascular, not related to abdominal 
aortic aneurysm 
8 (4·3) 0 (0) 7 (5·8) 1 (1·5)  
   Stroke 1 (0·5) 0 (0) 1 (0·8) 0(0)  
   Myocardial infarction 5 (2·7) 0 (0) 4 (3·3) 1 (1·5)  
   Other cardiovascular 2 (1·1) 0 (0) 2 (1·7) 0 (0)  
  Noncardiovascular 8 (4·3) 1 (50) 5 (4·2) 2 (3·1)  
   Malignancy 4 (2·1) 1 (50) 3 (2·5) 0 (0)  
   Other 4 (2·1) 0 (0) 2 (1·7) 0 (0)  
Values indicate n (%). CI indicates confidence interval; USPIO, ultrasmall superparamagnetic particles of iron oxide. 
*Fisher exact test because of small numbers.
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was not possible in a small number of patients because 
of contraindications or claustrophobia. However, it was 
a feasible, safe, and deliverable clinical technique that 
was well tolerated in the vast majority of patients with no 
serious adverse effects of the MRI or contrast medium. 
Moreover, we have demonstrated its applicability across 
multiple sites, and we have developed robust computer 
algorithms and image analysis techniques that enable au-
tomated reporting of USPIO enhancement, lending itself 
to immediate clinical application.
In conclusion, in a multicenter prospective observa-
tional cohort study, we have demonstrated that USPIO-
enhanced MRI predicts the rate of aneurysm expansion 
and the risk of abdominal aortic aneurysm rupture and 
repair. Although this study does not provide indepen-
dent prediction of aneurysm expansion or clinical out-
comes in a model incorporating known clinical risk fac-
tors, it is the first demonstration of a cellular imaging 
technique that can predict clinical events in patients with 
abdominal aortic aneurysm. Whether clinical outcomes 
can be improved by treatment decisions on the basis of 
this novel imaging approach remains to be established.
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